fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Anagrelide HCL

All products: Limited Use (codes 400)

PMS-Anagrelide · DIN 02274949 · 0.5 mg · capsule

Limited Use, Reason for Use code 400 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 400 required
Write on scriptReason for Use code 400 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 400
Reason for Use code 400 For the treatment of essential thrombocytosis in patients who are intolerant of or who have failed hydroxyurea therapy. Coverage limit: LU Authorization Period: 5 years.
1 brand, same coverage
PMS-Anagrelide · DIN 02274949 Manufacturer: Pharmascience Inc.; listing date 2020-02-28 Health Canada: Marketed since 2006-01-06 · brand PMS-ANAGRELIDE · ATC L01XX35 ANAGRELIDE · form Capsule · route Oral · ingredients ANAGRELIDE (ANAGRELIDE HYDROCHLORIDE MONOHYDRATE) 0.5 MG · company Pharmascience inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

PMS-Anagrelide: Formulary list price $4.70 per unit (the source does not state the unit; exact figure $4.6997). What the ministry pays, not the patient.

Ministry pays: $4.6997 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02274949)

Source record
DIN 02274949: PMS-Anagrelide Raw flags: sec12=Y, sec3=Y Item: 920000273; group id 896; item number 2151; lccId 00164; manufacturer id PMS Source form: Cap; strength: 0.5mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $4.6997; ministry $4.6997 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02274949 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76047
Interchangeable products
Agrylin · DIN 02236859 · not recorded
Shortage status: resolved shortage (ended October 7, 2025); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02274949
Shortage record checked October 6, 2026

Other products in the same Health Canada class (L01X): coverage varies; not interchangeable

  • Tretinoin (Vesanoid): not a benefit
Other drugs in the same formulary class (92:00 UNCLASSIFIED THERAPEUTIC AGENTS) and how they are covered

Matched class: 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ALENDRONATE & CHOLECALCIFEROL, AZATHIOPRINE, CYCLOSPORINE, GLUCAGON RDNA ORIGIN, LANREOTIDE ACETATE, LEFLUNOMIDE, LEVODOPA & BENSERAZIDE, MYCOPHENOLATE SODIUM, RISPERIDONE Some products covered without a code (check the product listing): ALENDRONATE, ALLOPURINOL, AMANTADINE HCL, BROMOCRIPTINE, CLOPIDOGREL BISULFATE, LEVODOPA & CARBIDOPA, MYCOPHENOLATE MOFETIL, OCTREOTIDE, RISEDRONATE SODIUM, ROPINIROLE, SELEGILINE HCL, TAMSULOSIN HCL 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

TRETINOIN

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 10mg · Cap

ALENDRONATE

· 28 products · Off-Formulary Interchangeable, not an ODB benefit (4), Listed, not a benefit (1), General benefit (23) · strengths: 5mg, 10mg, 70mg · Tab

ALENDRONATE & CHOLECALCIFEROL

· 6 products · General benefit · strengths: 70mg & 70mcg, 70mg & 140mcg · Tab

ALLOPURINOL

· 10 products · General benefit (6), Listed, not a benefit (4) · strengths: 100mg, 200mg, 300mg · Tab

AMANTADINE HCL

· 5 products · Listed, not a benefit (2), General benefit (3) · strengths: 100mg, 10mg/mL · Cap, O/L

AZATHIOPRINE

· 3 products · General benefit · strengths: 50mg · Tab

BROMOCRIPTINE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 5mg, 2.5mg · Cap, Tab

CLOPIDOGREL BISULFATE

· 19 products · General benefit (16), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 75mg, 300mg · Tab

CYCLOSPORINE

· 8 products · General benefit · strengths: 10mg, 25mg, 50mg, 100mg, 100mg/mL · Cap, O/L

GLUCAGON RDNA ORIGIN

· 2 products · General benefit · strengths: 1mg/Vial · Inj Pd-Syr Pk, Inj Pd-Vial Pk

LANREOTIDE ACETATE

· 6 products · General benefit · strengths: 60mg/Syr, 90mg/Syr, 120mg/Syr · ER Pref Syr Pk

LEFLUNOMIDE

· 16 products · General benefit · strengths: 10mg, 20mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 92:00 and 78 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS pms-ANAGRELIDE (anagrelide hydrochloride capsules) is indicated for: • Treatment of patients with thrombocythemia secondary to myeloproliferative neoplasms to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms, including thrombo-hemorrhagic events. pms-ANAGRELIDE is intended for chronic usage and has not been evaluated for treatment of the acute life-threatening complications of thrombocytosis. 1.1 Pediatrics The safety and efficacy of anagrelide hydrochloride in patients under 16 years of age have not been established. Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics The safety and effectiveness of anagrelide hydrochloride have not been evaluated in studies specific to the elderly. Health Canada has not authorized an indication for geriatric use. https://pdf.hres.ca/dpd_pm/00072682.PDF PM date: January 6, 2006 Source product: PMS-ANAGRELIDE; DIN 02274949; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.